PTAB statistics
PTAB Statistics: Fiscal Year 2023
In fiscal year 2023 (October 1, 2022 to September 30, 2023), 1,241 AIA trial petitions were filed: 1,209 IPR, 30 PGR, 0 CBM and 2 derivation. In the same period the Board instituted trial on 755 petitions and denied 365, an institution rate of 67.4% by petition. The Board issued 584 final written decisions, and 418 proceedings ended in settlement.
Key Facts
- Period
- October 1, 2022 to September 30, 2023
- Petitions filed
- 1,241
- Institution rate
- 67.4%
- Final written decisions
- 584
- Settlements
- 418
- Data retrieved
- October 31, 2026
On this page
This page reports Patent Trial and Appeal Board trial activity in fiscal year 2023, which ran from October 1, 2022 to September 30, 2023. Each figure is a count of USPTO Open Data Portal records; the methodology on the statistics page explains the counting rules.
Figures by Trial Type
Petitions are counted by filing date. Institution decisions, final written decisions and terminations are counted by the date of the event, so a petition filed in one fiscal year may be decided in the next.
| Measure | IPR | PGR | CBM | DER | Total |
|---|---|---|---|---|---|
| Petitions filed | 1,209 | 30 | 0 | 2 | 1,241 |
| Institution decisions: instituted | 731 | 24 | 0 | 0 | 755 |
| Institution decisions: denied | 357 | 8 | 0 | 0 | 365 |
| Institution rate (by petition) | 67.2% | 75.0% | — | — | 67.4% |
| Final written decisions | 563 | 20 | 0 | 1 | 584 |
| Terminations without a final written decision | Count |
|---|---|
| Settlements | 418 |
| Settled before institution | 187 |
| Settled after institution | 231 |
| Adverse judgment | 19 |
| Dismissed | 2 |
| Other terminations | 27 |
Figures by Trial Type in Detail
Inter Partes Review (IPR)
In FY2023, 1,209 IPR petitions were filed (97.4% of all AIA petitions). Of 1,088 IPR institution decisions, 731 instituted a trial and 357 denied institution, a rate of 67.2%. The Board issued 563 IPR final written decisions. An IPR may be instituted only on a reasonable likelihood that the petitioner will prevail on at least one claim (35 U.S.C. § 314(a)), on grounds of anticipation or obviousness over patents and printed publications. See the inter partes review guide for the procedure.
Post-Grant Review (PGR)
In FY2023, 30 PGR petitions were filed (2.4% of all AIA petitions). Of 32 PGR institution decisions, 24 instituted a trial and 8 denied institution, a rate of 75.0%. The Board issued 20 PGR final written decisions. A PGR petition must be filed within nine months of grant and must show that it is more likely than not that at least one claim is unpatentable (35 U.S.C. § 324(a)). See the post-grant review guide for the procedure.
Derivation Proceedings (DER)
In FY2023, 2 DER petitions were filed (0.2% of all AIA petitions). No DER institution decisions were recorded. The Board issued 1 DER final written decisions. Derivation proceedings decide whether an inventor named in an earlier application derived the claimed invention from the petitioner’s inventor; they are few in number, so rates rest on small counts. See the guide to the Patent Trial and Appeal Board for the procedure.
How Proceedings Ended
Of the proceedings that ended during the period, 584 ended in a final written decision under 35 U.S.C. § 318, 418 in settlement under 35 U.S.C. § 317 (187 before institution and 231 after), 19 in adverse judgment, 2 by dismissal and 27 by other termination. Denials of institution are counted separately above. A final written decision can lead to estoppel against the petitioner; see estoppel arising from PTAB trials.
Summary
- Inter partes review accounted for 97.4% of petitions filed.
- Petitions fell by 128 from FY2022 (1,369), a change of 9.3%.
- The institution rate rose by 2.1 percentage points from 65.3% in FY2022.
- By type, the institution rate was 67.2% for IPR petitions and 75.0% for PGR petitions.
- Of 1,050 proceedings that ended after institution or by settlement or other termination in the year, 584 (55.6%) ended in a final written decision.
Other Fiscal Years
FY2022 · FY2024 · All fiscal years and charts
Final written decision outcomes (all, some or no challenged claims unpatentable) are not reported because the USPTO records state them for too few decisions; see the methodology. Figures may differ from the USPTO’s published reports. For how trials end and why reported rates differ, see reading PTAB trial outcomes.
Frequently Asked Questions
How many PTAB petitions were filed in FY2023?
In fiscal year 2023 (October 1, 2022 to September 30, 2023), USPTO records show 1,241 AIA trial petitions: 1,209 IPR, 30 PGR, 0 CBM and 2 derivation.
What was the PTAB institution rate in FY2023?
By petition, 67.4%: 755 petitions instituted and 365 denied, counted by the date of the institution decision. For IPR alone the rate was 67.2%.
How many final written decisions did the PTAB issue in FY2023?
584, of which 563 were in inter partes reviews. In the same period 418 proceedings settled.
Primary Sources
Related Pages
- GuidePTAB StatisticsUSPTO records show 19,437 AIA trial petitions filed from September 16, 2012 to October 30, 2026: 18,227 inter…
- PTAB statisticsPTAB Statistics: Fiscal Year 2022In fiscal year 2022 (October 1, 2021 to September 30, 2022), 1,369 AIA trial petitions were filed: 1,320 IPR,…
- PTAB statisticsPTAB Statistics: Fiscal Year 2024In fiscal year 2024 (October 1, 2023 to September 30, 2024), 1,288 AIA trial petitions were filed: 1,250 IPR,…
- ArticleReading PTAB Trial Outcomes: Institution, Settlement and Final DecisionsAn AIA trial can end at several points: denial of institution, settlement and termination under 35 U.S.C. §…
- Proceedings guideInter Partes Review (IPR)Inter partes review is a trial before the Patent Trial and Appeal Board in which anyone other than the patent…
- Proceedings guidePost-Grant Review (PGR)Post-grant review lets anyone other than the patent owner challenge an issued patent on almost any ground of…
Educational information; not legal advice. Statutes, rules and USPTO practice change. Confirm against the primary sources and consult a registered patent practitioner before acting. Disclaimer.